마이크로 RNA 시장 : 예측(2026-2031년)

MicroRNA Market, at a 12.85% CAGR, is anticipated to reach USD 3.764 billion in 2031 from USD 1.822 billion in 2025.

The microRNA market is experiencing robust growth, with estimates placing its value between USD 1.8-2.0 billion in 2024 and projections reaching USD 6-10 billion by 2034, reflecting CAGRs of 12-19%. This expansion is fueled by escalating clinical trials exploring microRNA's diagnostic and therapeutic roles in complex diseases, particularly cancer. Rising cancer prevalence is accelerating demand for microRNA-based biomarkers and personalized therapies. Biotech firms are innovating tools for research, diagnostics, and treatments, while applications extend into agriculture, veterinary medicine, and environmental monitoring.

MicroRNAs (miRNAs) are small, non-coding RNA molecules (21-25 nucleotides) that regulate gene expression post-transcriptionally. Their dysregulation links to numerous pathologies, positioning them as biomarkers, therapeutic targets, and modulators. The market encompasses research tools (profiling assays, sequencing kits), services (functional analysis, custom synthesis), and emerging therapeutics (mimics, inhibitors). Growth stems from miRNA's broad-spectrum potential in oncology, cardiovascular, neurological, and infectious diseases, alongside technological synergies in NGS, bioinformatics, and delivery systems.

Primary drivers include intensifying clinical trials, with platforms like clinicaltrials.gov listing ongoing studies targeting miRNA pathways in solid tumors, hematological malignancies, and chronic conditions. Cancer's dominance-accounting for significant morbidity-propels miRNA as non-invasive biomarkers and oncomiR suppressors. The shift toward personalized medicine leverages miRNA profiles for patient stratification and tailored interventions.

Opportunities lie in diversifying applications beyond human health, including plant/agricultural trait enhancement, veterinary diagnostics, and ecological monitoring via miRNA signatures. Funding influxes support pipeline advancement, with candidates progressing through preclinical and early clinical phases.

Restraints encompass incomplete understanding of miRNA networks, challenges in specific delivery (stability, off-target effects), stringent validation for clinical utility, and regulatory hurdles for therapeutic approval.

Geographically, North America commands 40-48% share, driven by advanced research infrastructure, substantial R&D funding, high chronic disease burden, and key players' concentration. The U.S. leads through NIH-backed initiatives and biotech hubs. Asia-Pacific exhibits the fastest CAGR (up to 21%), fueled by population scale, rising healthcare investments, and genomic focus in China, Japan, and India.

Leading companies include Thermo Fisher Scientific (profiling/sequencing tools), QIAGEN (sample-to-insight workflows), Illumina (NGS platforms), Horizon Discovery (editing/modulation reagents), BioGenex (ISH detection), and emerging therapeutics firms like Regulus and MiRagen. These entities advance assay sensitivity, bioinformatics integration, and clinical-grade mimics/inhibitors.

Overall, the market is advancing dynamically, with miRNA's multifaceted roles catalyzing precision diagnostics and therapeutics amid chronic disease escalation and technological convergence.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

MicroRNA Market Segmentation

• By Type
• Products
• Services
• By Application
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others
• By End-User
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other End-users
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MICRORNA MARKET BY TYPE

• 5.1. Introduction
• 5.2. Products
• 5.3. Services

6. MICRORNA MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Infectious Diseases
• 6.4. Immunological Disorder
• 6.5. Cardiovascular Disease
• 6.6. Neurological Disease
• 6.7. Others

7. MICRORNA MARKET BY END-USER

• 7.1. Introduction
• 7.2. Biotechnology & Pharmaceutical Companies
• 7.3. Academic & Government Research Institutes
• 7.4. Other end-users

8. MICRORNA MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific, Inc.
• 10.2. Horizon Discovery Ltd.
• 10.3. QIAGEN
• 10.4. BioGenex
• 10.5. GeneCopoeia, Inc.
• 10.6. NanoString
• 10.7. Quantabio
• 10.8. SeqMatic LLC
• 10.9. OriGene Technologies, Inc.
• 10.10. Illumina, Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations